EMI 137

Drug Profile

EMI 137

Alternative Names: EMI137; GE 137

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer Edinburgh Molecular Imaging; GE Healthcare; Kings College London; University Medical Center Groningen
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Breast cancer; Orofacial cancer
  • Phase I Barrett's oesophagus

Most Recent Events

  • 04 Dec 2017 Phase-II clinical trials in Colorectal cancer (Diagnosis, In adults, In the elderly) in United Kingdom (IV) (NCT03360461)
  • 20 Sep 2017 Edinburgh Molecular Imaging plans a clinical trials for Breast Cancer, Gastric Cancer, Thyroid Cancer, Head & Neck Cancer, Prostate Cancer and Brain Cancer (Diagnosis) in USA, United Kingdom, European Union and Asia
  • 20 Sep 2017 Phase-II clinical trials in Colorectal cancer (Diagnosis, In adults) in Netherlands (IV) (EudraCT2016-002827-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top